A Phase 3 interventional study of Bempedoic Acid + Ezetimibe Fixed-Dose Combination and Bempedoic Acid in Hyperlipidemias, sponsored by Esperion Therapeutics, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-08.
Sponsored by Esperion Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing ezetimibe in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. Ezetimibe · Hyperlipidemias.
Among the 12 studies testing ezetimibe in Hyperlipidemias, this one is the 2nd largest by enrollment, is the only one that started in 2017, is one of 4 in phase 3, and was the 11th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →None of the 12 studies testing ezetimibe in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 382 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 139 across the 12 interventional studies. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 12 have an industry lead sponsor. The 10 most frequent:
Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Esperion Therapeutics, Inc. has 9 studies filed under Hyperlipidemias — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing ezetimibe in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if Bempedoic Acid (BA) + Ezetimibe (EZE) in a fixed-dose combination (FDC) is effective and safe versus its individual components and placebo in patients with elevated LDL cholesterol treated with maximally tolerated statin therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Bempedoic acid (BA) + ezetimibe (EZE) fixed-dose combination (FDC) 180 mg/10 mg tablets taken orally once daily for 12 weeks
Combination Product: Bempedoic Acid + Ezetimibe Fixed-Dose Combination · Drug: Placebos
Bempedoic acid (BA) 180 mg tablets taken orally once daily for 12 weeks
Drug: Bempedoic Acid · Drug: Placebos
Ezetimibe (EZE) 10 mg overencapsulated tablets taken orally once daily for 12 weeks
Drug: Ezetimibe · Drug: Placebos
Placebos to match identical bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or identical bempedoic acid 180 mg tablet, or identical ezetimibe 10 mg capsule, taken orally, once daily for 12 weeks
Drug: Placebos
Drug pages: Bempedoic acid · Ezetimibe
bempedoic acid + ezetimibe FDC 180 mg/10 mg tablet
Also known as: Bempedoic Acid + Zetia FDC, ETC-1002 + Zetia
bempedoic acid 180 mg tablet
Also known as: ETC-1002
ezetimibe 10 mg overencapsulated tablet
Also known as: Zetia
placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule
Also known as: Placebo
Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the LDL-C values from Week -2 and predose Day 1/Week 0. Percent change from baseline in LDL-C was analyzed using analysis of covariance (ANCOVA) with treatment group and randomization stratification as a factors and baseline LDL-C as a covariate. Percent change from baseline was calculated as: (\[LDL-C value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100. For LDL-C, if measured LDL-C value was available, measured LDL-C was used.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the predose Day 1/Week 0 value. Percent change from baseline in hsCRP was analyzed using a non-parametric analysis. Percent change from baseline was calculated as: (\[hsCRP value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the non-HDL-C values from Week -2 and predose Day 1/Week 0. Percent change from baseline in non-HDL-C was analyzed using ANCOVA with treatment group and randomization stratification as a factors and baseline non-HDL-C as a covariate. Percent change from baseline was calculated as: (\[non-HDL-C value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 12 in Total Cholesterol (TC)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the TC values from Week -2 and predose Day 1/Week 0. Percent change from baseline in TC was analyzed using ANCOVA with treatment group and randomization stratification as a factors and baseline TC as a covariate. Percent change from baseline was calculated as: (\[TC value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 12 in Apolipoprotein B (Apo B)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apo B. Baseline was defined as the predose Day 1/Week 0 value. Percent change from baseline in apo B was analyzed using ANCOVA with treatment group and randomization stratification as a factors and baseline apo B as a covariate. Percent change from baseline was calculated as: (\[apo B value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for HDL-C. Baseline was defined as the mean of the HDL-C values from Week -2 and predose Day 1/Week 0. Percent change from baseline was calculated as: (\[HDL-C value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 12 in Triglycerides (TGs)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TGs. Baseline was defined as the mean of the TGs values from Week -2 and predose Day 1/Week 0. Percent change from baseline was calculated as: (\[TGs value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100.
Time frame: Baseline; Week 12
| Milestone | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo |
|---|---|---|---|---|
| Started | 108 | 110 | 109 | 55 |
| Completed | 103 | 103 | 104 | 53 |
| Not completed | 5 | 7 | 5 | 2 |
| Withdrew: Adverse event | 2 | 3 | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 2 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the LDL-C values from Week -2 and predose Day 1/Week 0. Percent change from baseline in LDL-C was analyzed using analysis of covariance (ANCOVA) with treatment group and randomization stratification as a factors and baseline LDL-C as a covariate. Percent change from baseline was calculated as: (\[LDL-C value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100. For LDL-C, if measured LDL-C value was available, measured LDL-C was used.
| Percent Change | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) | -36.2 ± 2.56 | -17.2 ± 2.52 | -23.2 ± 2.18 | 1.8 ± 3.49 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the predose Day 1/Week 0 value. Percent change from baseline in hsCRP was analyzed using a non-parametric analysis. Percent change from baseline was calculated as: (\[hsCRP value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100.
| Percent Change | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP) | -35.1 (-56.5 to -2.3) | -31.9 (-62.6 to 7.7) | -8.2 (-34.4 to 32.0) | 21.6 (-18.5 to 68.5) |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the non-HDL-C values from Week -2 and predose Day 1/Week 0. Percent change from baseline in non-HDL-C was analyzed using ANCOVA with treatment group and randomization stratification as a factors and baseline non-HDL-C as a covariate. Percent change from baseline was calculated as: (\[non-HDL-C value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100.
| Percent change | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) | -31.9 ± 2.23 | -14.1 ± 2.17 | -19.9 ± 2.05 | 1.8 ± 3.28 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the TC values from Week -2 and predose Day 1/Week 0. Percent change from baseline in TC was analyzed using ANCOVA with treatment group and randomization stratification as a factors and baseline TC as a covariate. Percent change from baseline was calculated as: (\[TC value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100.
| Percent change | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Total Cholesterol (TC) | -26.4 ± 1.90 | -12.1 ± 1.83 | -16.0 ± 1.59 | 0.7 ± 2.46 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apo B. Baseline was defined as the predose Day 1/Week 0 value. Percent change from baseline in apo B was analyzed using ANCOVA with treatment group and randomization stratification as a factors and baseline apo B as a covariate. Percent change from baseline was calculated as: (\[apo B value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100.
| Percent change | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Apolipoprotein B (Apo B) | -24.6 ± 2.38 | -11.8 ± 2.18 | -15.3 ± 1.97 | 5.5 ± 2.97 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for HDL-C. Baseline was defined as the mean of the HDL-C values from Week -2 and predose Day 1/Week 0. Percent change from baseline was calculated as: (\[HDL-C value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100.
| Percent change | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C) | -5.59 ± 12.269 | -5.40 ± 14.688 | -2.11 ± 11.590 | -0.54 ± 12.799 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TGs. Baseline was defined as the mean of the TGs values from Week -2 and predose Day 1/Week 0. Percent change from baseline was calculated as: (\[TGs value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100.
| Percent change | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Triglycerides (TGs) | -7.90 ± 25.633 | 7.94 ± 42.312 | -2.46 ± 33.402 | 5.47 ± 31.992 |
Collected over Up to approximately 14 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | 0/107 (0%) | 8/107 (7.5%) | 26/107 (24.3%) |
| Bempedoic Acid 180 mg | 0/110 (0%) | 7/110 (6.4%) | 27/110 (24.5%) |
| Ezetimibe 10 mg | 0/109 (0%) | 10/109 (9.2%) | 26/109 (23.9%) |
| Placebo | 0/55 (0%) | 1/55 (1.8%) | 12/55 (21.8%) |
| Event | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo |
|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 1/107 | 2/110 | 3/109 | 0/55 |
| Coronary artery diseaseCardiac disorders | 1/107 | 0/110 | 0/109 | 1/55 |
| Myocardial infarctionCardiac disorders | 0/107 | 1/110 | 0/109 | 1/55 |
| Angina pectorisCardiac disorders | 1/107 | 0/110 | 0/109 | 0/55 |
| Atrial fibrillationCardiac disorders | 1/107 | 0/110 | 0/109 | 0/55 |
| Myocardial ischaemiaCardiac disorders | 1/107 | 0/110 | 0/109 | 0/55 |
| Non-cardiac chest painGeneral disorders | 1/107 | 0/110 | 0/109 | 0/55 |
| Rhinovirus infectionInfections and infestations | 1/107 | 0/110 | 0/109 | 0/55 |
| HemiparesisNervous system disorders | 1/107 | 0/110 | 0/109 | 0/55 |
| Cardiac failure congestiveCardiac disorders | 0/107 | 0/110 | 1/109 | 0/55 |
| Event | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo |
|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 8/107 | 3/110 | 3/109 | 2/55 |
| NasopharyngitisInfections and infestations | 4/107 | 6/110 | 4/109 | 1/55 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/107 | 5/110 | 2/109 | 1/55 |
| HypertensionVascular disorders | 3/107 | 5/110 | 2/109 | 0/55 |
| ConstipationGastrointestinal disorders | 4/107 | 0/110 | 2/109 | 0/55 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/107 | 4/110 | 4/109 | 2/55 |
| Back painMusculoskeletal and connective tissue disorders | 3/107 | 3/110 | 4/109 | 2/55 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 2/107 | 1/110 | 4/109 | 0/55 |
| AnaemiaBlood and lymphatic system disorders | 1/107 | 2/110 | 1/109 | 2/55 |
| HeadacheNervous system disorders | 2/107 | 4/110 | 2/109 | 1/55 |
Data are presented for the Full Analysis Set, comprised of all randomized participants. One participant was randomized but was not treated.
| Age, Continuous(Years) | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 63.0 ± 9.97 | 65.2 ± 9.54 | 64.4 ± 8.91 | 65.6 ± 10.74 | 64.4 ± 9.68 |
| Sex: Female, Male(Participants) | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 58 | 65 | 57 | 22 | 202 |
| Male | 50 | 45 | 52 | 33 | 180 |
| Ethnicity (NIH/OMB)(Participants) | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 32 | 33 | 32 | 20 | 117 |
| Not Hispanic or Latino | 76 | 77 | 77 | 35 | 265 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 2 | 1 | 1 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 20 | 19 | 16 | 7 | 62 |
| White | 85 | 90 | 91 | 48 | 314 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Low-density lipoprotein cholesterol (LDL-C)(milligrams per deciliter (mg/dL)) | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 153.80 ± 40.526 | 145.13 ± 38.456 | 148.80 ± 41.839 | 152.80 ± 46.773 | 149.70 ± 41.162 |
| Non-high-density lipoprotein cholesterol (non-HDL-C)(mg/dL) | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 188.22 ± 46.657 | 175.67 ± 40.474 | 180.18 ± 47.308 | 180.91 ± 49.720 | 181.26 ± 45.595 |
| Total cholesterol (TC)(mg/dL) | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 237.32 ± 48.694 | 225.55 ± 43.165 | 231.41 ± 50.478 | 231.27 ± 50.210 | 231.36 ± 47.857 |
| Apolipoprotein B (apo B)(mg/dL) | Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 121.1 ± 30.85 | 113.4 ± 26.43 | 115.5 ± 31.30 | 115.1 ± 32.52 | 116.4 ± 29.98 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2017 to primary completion in Jun 2018, 7 months.
Results were first posted in Apr 2020, 1 year 9 months after primary completion. A results delay was requested in Sep 2018.
Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.
Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bempedoic acid · Ezetimibe